Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;4(5):878-882.
doi: 10.3892/ol.2012.862. Epub 2012 Aug 14.

Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis

Affiliations

Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis

Zhi Li Liu et al. Oncol Lett. 2012 Nov.

Abstract

Previous experimental evidence has suggested that fatty acid synthase (FASN) may be involved in cancer metastasis. However, its role has been poorly evaluated in osteosarcoma. The aim of this study was to investigate the correlation of FASN expression with pulmonary metastasis and the correlation of FASN expression with the Ki-67 antigen, a proliferation marker, in patients with osteosarcoma of the extremities. The expression of FASN protein and Ki-67 was detected by immunohistochemistry of biopsy tissues from 136 patients with osteosarcoma of the extremities and 21 cases of osteoenchondroma. Positive expression of the FASN protein was observed and located in the cytoplasm. The positive expression rate of FASN was 63.2% in osteosarcoma and 28.6% in osteoenchondroma (p<0.05). The expression levels of the FASN protein were higher in the cases with lung metastasis compared to those without metastasis (p<0.01). The percentage of Ki-67 stained nuclei in osteosarcoma with pulmonary metastasis and in those without was 43.43±10.05 and 25.41±6.68%, respectively (p<0.01). There was a positive correlation between FASN and Ki-67 protein expression in osteosarcoma (Spearman's rho, F=43.05, R=0.734). Therefore, FASN may be a promising target in the treatment of osteosarcoma metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fatty acid synthase (FASN) and Ki-67 expression in osteosarcoma (OS) and osteoenchondroma tissues (x400). Representative images of (a) H&E staining for osteoenchondroma tissues; (b) IHC staining for FASN in osteoenchondroma tissues; (c) IHC staining for Ki-67 in osteoenchondroma tissues; (d) H&E staining for OS tissues; (e) IHC staining for FASN in OS tissues; (f) IHC staining for Ki-67 in OS tissues. H&E, hematoxylin and eosin; IHC, immunohistochemistry.
Figure 2
Figure 2
Ki-67 expression in osteosarcoma (OS) with and without pulmonary metastasis (x400). Representative images of (a) H&E staining for OS tissues without pulmonary metastasis; (b) IHC staining for Ki-67 in OS tissues without pulmonary metastasis; (c) H&E staining for OS tissues with pulmonary metastasis and (d) IHC staining for Ki-67 with pulmonary metastasis. H&E, hematoxylin and eosin; IHC, immunohistochemistry.
Figure 3
Figure 3
Fatty acid synthase (FASN) expression in osteosarcoma (OS) with and without pulmonary metastasis (x400). Representative images of (a) H&E staining for OS tissues without pulmonary metastasis showing that OS is cell-rich and has significant cellular atypia, ansionucleosi, prominent nucleoli, abundant cytoplasm and a small amount of bone-like matrix; (b) IHC staining for FASN in OS tissues without pulmonary metastasis, showing yellow particle deposition in the cytoplasm with only a small amount of the cells, approximately 10%, colored; (c) H&E staining for OS tissues with pulmonary metastasis showing that OS is cell-rich and has significant cellular atypia, ansionucleosi, prominent nucleoli and abundant cytoplasm; (d) IHC staining for FASN with lung metastasis showing brown particles deposited in the cytoplasm with the majority of cells, approximately 92%, colored. H&E, hematoxylin and eosin; IHC, immunohistochemistry.

Similar articles

Cited by

References

    1. Longhi A, Errani C, De Paolis M, et al. Primary bone OS in the pediatric age: State of the art. Cancer Treatment Reviews. 2006;32:423–436. - PubMed
    1. Mckenna R, Schwinn CP, Soong KY, et al. Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone) an analysis of 552 cases. J Bone Joint Surg. 1966;48:1–26.
    1. Iwamoto Y, Tanaka K, Isu K, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for OS (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009;14:397–404. - PubMed
    1. Meyers PA, Schwartz CL, Krailo M, et al. OS: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011. - PubMed
    1. Jawad MU, Cheung MC, et al. Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol. 2011;137:597–607. - PMC - PubMed

LinkOut - more resources